Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bausch Health Companies (BHC – Research Report) and Arcus Biosciences (RCUS – Research Report).
Bausch Health Companies (BHC)
RBC Capital analyst Douglas Miehm assigned a Hold rating to Bausch Health Companies today and set a price target of $12.00. The company’s shares closed last Thursday at $8.97.
According to TipRanks.com, Miehm is a 1-star analyst with an average return of
Currently, the analyst consensus on Bausch Health Companies is a Hold with an average price target of $10.50.
See the top stocks recommended by analysts >>
Arcus Biosciences (RCUS)
In a report issued on April 10, Kaveri Pohlman from BTIG maintained a Buy rating on Arcus Biosciences, with a price target of $70.00. The company’s shares closed last Thursday at $17.29.
According to TipRanks.com, Pohlman is a 3-star analyst with an average return of
Currently, the analyst consensus on Arcus Biosciences is a Strong Buy with an average price target of $40.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on BHC:
